Company Encyclopedia
View More
name
ZBD
603567.SH
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
3.159 T
603567.SHMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking187/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-4.42%D
    • Profit Margin-20.85%D
    • Gross Margin-1.04%E
  • Growth ScoreE
    • Revenue YoY-48.84%E
    • Net Profit YoY-150.91%E
    • Total Assets YoY-7.13%D
    • Net Assets YoY-11.66%E
  • Cash ScoreE
    • Cash Flow Margin-479.51%E
    • OCF YoY-48.84%E
  • Operating ScoreE
    • Turnover0.13E
  • Debt ScoreB
    • Gearing Ratio38.22%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ZBD's controlling shareholder passively reduced its holdings due to bond conversion, with shareholding dropping to 59.87%

    Heilongjiang ZBD Pharmaceutical's controlling shareholder Chuangda Group passively reduced its holdings due to bond conversion, with its shareholding ratio decreasing from 60.85% to 59.87%. From August 2 to September 18, Chuangda Group converted a total of 16,550,986 shares through exchangeable bonds, accounting for 1.76% of the total share capital. This change does not trigger a mandatory takeover bid, and the controlling shareholder and actual controller have not changed. The company will continue to monitor the share conversion matters and disclose relevant information in accordance with the law, reminding investors to pay attention to risks

    Zhitong·
    SH
    603567
    +1.39%
    Zhitong·
    SH
    603567
    +1.39%

    ZBD Pharmaceuticals' shareholder Huzhou Saihan reduced its holdings, bringing its stake down to 5%

    Heilongjiang Zhenbao Island Pharmaceutical announced that its shareholder Huzhou Saihan, holding more than 5% of shares, has implemented a reduction plan, selling 48,354 shares through centralized bidding on September 10. Previously, due to the company's repurchase and cancellation of restricted stocks, Huzhou Saihan's shareholding ratio increased passively. After this change in equity, its holdings decreased to 47,049,826 shares, and the ratio fell to 5%, no longer qualifying as a shareholder holding more than 5%. This change does not trigger a tender offer and does not alter the company's controlling rights. The reduction plan has not been fully implemented, and the company will closely monitor the progress and urge disclosure

    Zhitong·
    SH
    603567
    +1.39%
    Zhitong·
    SH
    603567
    +1.39%

    ZBD: Net profit loss of 78.2899 million yuan in the first half of 2025

    ZBD announced that in the first half of 2025, operating revenue was 713 million yuan, a year-on-year decrease of 57.04%. The net profit loss was 78.2899 million yuan, compared to a net profit of 393 million yuan in the same period last year

    Zhitong·
    SH
    603567
    +1.39%
    Zhitong·
    SH
    603567
    +1.39%

    ZBD: The conversion price of the convertible bonds held by the controlling shareholder will be adjusted from RMB 13.35 per share to RMB 12.35 per share

    Heilongjiang ZBD Pharmaceutical Co., Ltd.'s controlling shareholder Heilongjiang Chuangda Group Co., Ltd. announced that the conversion price of the first phase of the convertible bonds "23 Chuang 01EB" will be adjusted from RMB 13.35 per share to RMB 12.35 per share. This adjustment aims to protect the interests of the holders and has been approved by the board of directors and the bondholders' meeting. The adjustment will take effect on August 27

    Zhitong·
    SH
    603567
    +1.39%
    Zhitong·
    SH
    603567
    +1.39%

    ZBD: The approval notice for the listing application of fumaric acid lupatadine as a chemical raw material drug has been obtained

    ZBD announced that its Jixi branch has received the approval notice for the marketing application of Fumaric Acid Lurasidone chemical raw materials issued by the National Medical Products Administration. Fumaric Acid Lurasidone is a long-acting antihistamine that acts on H1 receptors. The company has invested approximately RMB 6.6526 million in research and development expenses for this project

    Zhitong·
    SH
    603567
    +1.39%
    Zhitong·
    SH
    603567
    +1.39%
    © 2025 Longbridge｜Disclaimer